https://www.live-feeds.com/feed/new-pancreatic-cancer-drug-carries-a-39-800-monthly-list-price-what-to-knowContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/new-pancreatic-cancer-drug-carries-a-39-800-monthly-list-price-what-to-knowhttps://www.live-feeds.com/feed/new-pancreatic-cancer-drug-carries-a-39-800-monthly-list-price-what-to-know#u52644Mon, 31 Aug 2026 02:45:48 +0000The FDA has granted speedy approval to daraxonrasib, marketed as RASONQUE, a pancreatic cancer drug developed by Revolution Medicines. The treatment costs $39,800 per month. Clinical data shows the drug improves patient survival and extends lives for those with a disease known for high mortality rates. Market analysts expect the drug to become a blockbuster for the independent developer. While the approval is described as a landmark moment by researchers, some critics argue that potential government budget cuts could limit patient access to the therapy.Why it mattersPancreatic cancer typically https://www.live-feeds.com/feed/new-pancreatic-cancer-drug-carries-a-39-800-monthly-list-price-what-to-knowhttps://www.live-feeds.com/feed/new-pancreatic-cancer-drug-carries-a-39-800-monthly-list-price-what-to-know#u51553Sat, 29 Aug 2026 09:06:21 +0000The FDA has approved daraxonrasib, marketed as RASONQUE, to treat pancreatic cancer. The drug carries a monthly list price of $39,800. Analysts expect the treatment to become a blockbuster for Revolution Medicines, the developer of the drug. This approval provides a new therapeutic option for a disease characterized by high mortality rates.Why it mattersPancreatic cancer is known as a deadly disease with limited treatment options. The introduction of a breakthrough drug like daraxonrasib represents a shift in the medical approach to this specific malignancy.What is confirmedThe FDA approved th